OptimizeRx Co. (NASDAQ:OPRX) Given Consensus Rating of “Moderate Buy” by Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has received an average rating of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $9.06.

Several analysts recently weighed in on the stock. B. Riley raised shares of OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. Stephens initiated coverage on shares of OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective on the stock. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 price target (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price objective on shares of OptimizeRx in a research report on Thursday, February 6th.

Insiders Place Their Bets

In related news, Director James Paul Lang purchased 321,408 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the transaction, the director now directly owns 389,452 shares of the company’s stock, valued at approximately $2,959,835.20. The trade was a 472.35 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Delta Investment Management LLC purchased a new position in OptimizeRx in the 4th quarter valued at $146,000. Squarepoint Ops LLC raised its stake in shares of OptimizeRx by 298.8% during the 4th quarter. Squarepoint Ops LLC now owns 41,712 shares of the company’s stock worth $203,000 after buying an additional 31,252 shares in the last quarter. Tang Capital Management LLC acquired a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $1,075,000. Graham Capital Management L.P. acquired a new position in OptimizeRx during the fourth quarter worth $81,000. Finally, D. E. Shaw & Co. Inc. raised its position in OptimizeRx by 12.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company’s stock worth $1,437,000 after acquiring an additional 32,062 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Trading Up 5.2 %

OPRX opened at $9.47 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The stock has a market capitalization of $174.45 million, a price-to-earnings ratio of -7.12 and a beta of 1.31. The business has a fifty day moving average price of $6.02 and a 200 day moving average price of $5.94. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $14.13.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.